IBDEI0S2 ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,12909,0)
 ;;=J2778^^79^751^6^^^^1
 ;;^UTILITY(U,$J,358.3,12909,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,12909,1,2,0)
 ;;=2^Ranibizumab Inj per 0.1mg
 ;;^UTILITY(U,$J,358.3,12909,1,3,0)
 ;;=3^J2778
 ;;^UTILITY(U,$J,358.3,12910,0)
 ;;=J3301^^79^751^5^^^^1
 ;;^UTILITY(U,$J,358.3,12910,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,12910,1,2,0)
 ;;=2^Kenalog Inj per 10mg
 ;;^UTILITY(U,$J,358.3,12910,1,3,0)
 ;;=3^J3301
 ;;^UTILITY(U,$J,358.3,12911,0)
 ;;=J0178^^79^751^1^^^^1
 ;;^UTILITY(U,$J,358.3,12911,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,12911,1,2,0)
 ;;=2^Aflibercept Inj 1mg
 ;;^UTILITY(U,$J,358.3,12911,1,3,0)
 ;;=3^J0178
 ;;^UTILITY(U,$J,358.3,12912,0)
 ;;=C9257^^79^751^2^^^^1
 ;;^UTILITY(U,$J,358.3,12912,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,12912,1,2,0)
 ;;=2^Bevacizumab Inj 0.25 mg
 ;;^UTILITY(U,$J,358.3,12912,1,3,0)
 ;;=3^C9257
 ;;^UTILITY(U,$J,358.3,12913,0)
 ;;=J9400^^79^751^7^^^^1
 ;;^UTILITY(U,$J,358.3,12913,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,12913,1,2,0)
 ;;=2^ZIV-Aflibercept 1 mg
 ;;^UTILITY(U,$J,358.3,12913,1,3,0)
 ;;=3^J9400
 ;;^UTILITY(U,$J,358.3,12914,0)
 ;;=4450F^^79^752^2^^^^1
 ;;^UTILITY(U,$J,358.3,12914,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,12914,1,2,0)
 ;;=2^Self-Care Ed Provided to Pt
 ;;^UTILITY(U,$J,358.3,12914,1,3,0)
 ;;=3^4450F
 ;;^UTILITY(U,$J,358.3,12915,0)
 ;;=4177F^^79^752^3^^^^1
 ;;^UTILITY(U,$J,358.3,12915,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,12915,1,2,0)
 ;;=2^Talk Pt/Crgvr Re AREDS
 ;;^UTILITY(U,$J,358.3,12915,1,3,0)
 ;;=3^4177F
 ;;^UTILITY(U,$J,358.3,12916,0)
 ;;=4174F^^79^752^1^^^^1
 ;;^UTILITY(U,$J,358.3,12916,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,12916,1,2,0)
 ;;=2^Couns Potent Glauc Impct
 ;;^UTILITY(U,$J,358.3,12916,1,3,0)
 ;;=3^4174F
 ;;^UTILITY(U,$J,358.3,12917,0)
 ;;=B02.33^^80^753^161
 ;;^UTILITY(U,$J,358.3,12917,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12917,1,3,0)
 ;;=3^Zoster Keratitis
 ;;^UTILITY(U,$J,358.3,12917,1,4,0)
 ;;=4^B02.33
 ;;^UTILITY(U,$J,358.3,12917,2)
 ;;=^5000496
 ;;^UTILITY(U,$J,358.3,12918,0)
 ;;=B02.32^^80^753^160
 ;;^UTILITY(U,$J,358.3,12918,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12918,1,3,0)
 ;;=3^Zoster Iridocyclitis
 ;;^UTILITY(U,$J,358.3,12918,1,4,0)
 ;;=4^B02.32
 ;;^UTILITY(U,$J,358.3,12918,2)
 ;;=^5000495
 ;;^UTILITY(U,$J,358.3,12919,0)
 ;;=B00.52^^80^753^82
 ;;^UTILITY(U,$J,358.3,12919,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12919,1,3,0)
 ;;=3^Herpesviral Keratitis
 ;;^UTILITY(U,$J,358.3,12919,1,4,0)
 ;;=4^B00.52
 ;;^UTILITY(U,$J,358.3,12919,2)
 ;;=^5000474
 ;;^UTILITY(U,$J,358.3,12920,0)
 ;;=B00.51^^80^753^81
 ;;^UTILITY(U,$J,358.3,12920,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12920,1,3,0)
 ;;=3^Herpesviral Iridocyclitis
 ;;^UTILITY(U,$J,358.3,12920,1,4,0)
 ;;=4^B00.51
 ;;^UTILITY(U,$J,358.3,12920,2)
 ;;=^5000473
 ;;^UTILITY(U,$J,358.3,12921,0)
 ;;=B30.8^^80^753^47
 ;;^UTILITY(U,$J,358.3,12921,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12921,1,3,0)
 ;;=3^Conjunctivitis,Viral NEC
 ;;^UTILITY(U,$J,358.3,12921,1,4,0)
 ;;=4^B30.8
 ;;^UTILITY(U,$J,358.3,12921,2)
 ;;=^88239
 ;;^UTILITY(U,$J,358.3,12922,0)
 ;;=C69.41^^80^753^113
 ;;^UTILITY(U,$J,358.3,12922,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12922,1,3,0)
 ;;=3^Malig Neop of Right Ciliary Body
 ;;^UTILITY(U,$J,358.3,12922,1,4,0)
 ;;=4^C69.41
 ;;^UTILITY(U,$J,358.3,12922,2)
 ;;=^5001279
 ;;^UTILITY(U,$J,358.3,12923,0)
 ;;=C69.42^^80^753^111
 ;;^UTILITY(U,$J,358.3,12923,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12923,1,3,0)
 ;;=3^Malig Neop of Left Ciliary Body
 ;;^UTILITY(U,$J,358.3,12923,1,4,0)
 ;;=4^C69.42
